ERYTHROPOIETIN RESTORES MOTOR FUNCTIONS THROUGH ANGIOGENESIS IN THE THALAMUS AREA OF ISCHEMIC STROKE IN RATS

Rifda Naufa Lina, Mahardian Rahmadi, Junaidi Khotib
Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

ABSTRACT

The present study aimed to determine the potency of erythropoietin as angiogenesis inducer in ischemic stroke rats model. Animal model was treated by right unilateral common carotid artery occlusion (rUCCAO) for 90 minutes. The stroke model produced decreased motor function. Eight to 12 week-old Wistar rats were used. rHuEPO was administered for 7 days, starting at 24 hours after stroke induction. Motor functions were measured before and 1, 3 and 7 days after rUCCAO. Whereas, histological damage and VEGF expression were evaluated at day 14. The results showed that rHuEPO significantly increased motor function on day 7, reduced the number of damaged body cell and increased VEGF expression in the thalamus area on day 14. As a conclusion, rHuEPO may restore the motoric function and prevent brain neuronal death by inducing angiogenesis through the increase in the expression of VEGF in rUCCAO-induced ischemic stroke model.

Keywords: rHuEPO; ischemic stroke; motor function; angiogenesis; VEGF

INTRODUCTION

Stroke is one of common causes of disability and death (Park et al 2014). Ischemic stroke is caused by focal occlusion of cerebral blood vessels, leading to the decrease in oxygen and nutrition supply to the brain and causing neuronal death in certain brain area (Park et al 2014, Hacke et al 2003). Occlusion can be thrombus, embolus, or thromboembolic which can cause hypoxia to anoxia at one of the branching of blood vessels in the brain (Bruno et al 2000). Approximately 30.7 million people in the world suffer from stroke every year. Around 800,000 primary or recurrent strokes happen each year in the U.S., with the most common are primary strokes. Approximately 87% are ischemic infarctions, 10% are primary hemorrhages, and 3% are subarachnoid hemorrhage (Ovbiagele & Huynh 2011).

In ischemic stroke, reduced blood flow to the brain causes hypoxemia of the brain region causing infarct core and penumbra that ends with cell death (Gonzalez et al 2011). Ischemic penumbra was defined as underperfused brain tissue at level within the thresholds of functional impairment and morphological integrity. The penumbra area has the capacity to recover if perfusion is restored. The core is generally defined as that part of the ischemic region that is irreversibly injured (Gonzalez et al 2011). It can be induced by microglia activation and release several cytokines such as IL-1 and TNF-α that is a member of the cell death receptor (Jin et al 2010, Deb
et al 2009, Pun et al 2009, Vikman et al 2007). Thus, the study suggested ischemic stroke therapy targeted to the ischemic penumbra.

Hypoxia induces cells to respond through multiple gene products, such as EPO and VEGF, that will improve oxygen delivery to the tissues. The induction of EPO and EPOR by hypoxia suggests that EPO administration has a therapeutic potential role for tissue damage from ischemia or hypoxia in the central nervous system (Ribatti et al 2003). A critical molecular pathway induced by hypoxia/ischemia is the activation of hypoxia-inducible factor 1, a transcriptional activator of genes encoding VEGF and other important mediators of angiogenesis. Hif1α is the central transcriptional factor for the regulation of oxygen-associated genes in response to hypoxia (Gandin et al 2016). In the key restorative mechanisms in response to stroke, there is increasing evidences that angiogenesis, through new blood vessel formation, results in improved collateral circulation and may impact the long-term recovery of the patients (Gandin et al 2016).

Recombinant EPO may also provide neuroprotection via its interaction with other growth factors, such as vascular endothelial growth factor (VEGF) and insulin growth factor (IGF-1). EPO has robust angiogenic effects and works synergistically with VEGF. Increased angiogenesis during recovery from a stroke injury might improve oxygen transport to healing brain areas (Hoke 2006). EPO/EPOR mRNA and protein were detected in several regions of the murine and primate brain, including cortex, hippocampus, amygdala, cerebellum, hypothalamus, and caudate nucleus. Recent findings show that astrocytes are the main source of EPO in the brain. Moreover, it has been shown in in vitro and in vivo studies that neurons express EPO. Similarly, EPO receptor (EPOR) is expressed on neurons and astrocytes. EPO promotes cell survival through inhibiting apoptosis. In erythroid cells, after EPO binding to its EPOR, Janus tyrosine kinase 2 (JAK2) is phosphorylated and activated. This leads to engaging secondary signaling molecules, such as signal transducer and activator of transcription 5 (STAT5), followed by the activation of Ras mitogen activated protein kinase (MAPK), ERK-1/-2, and PI3K/Akt. Moreover, EPO induced the upregulation of the anti-apoptotic protein BCL-XL (Rabie & Marti 2008). PI3K/Akt and ERK1/2 signaling pathways mediate VEGF secretion by the interaction of exogenous EPO with EPOR in neural progenitor cells. Furthermore, VEGF secreted by neural progenitor cells along with VEGF-R2 in cerebral endothelial cells promotes angiogenesis (Wang et al 2008). EPO increases VEGF that mediates rHuEPO-induced angiogenesis (Wang et al 2004).

Since EPO may induce angiogenesis, it is possible that the motoric defect after ischemic stroke-induced transient right unilateral common carotid artery is ameliorated by EPO treatment. We hypothesized that EPO induces angiogenesis to improve the collateral circulation, leading to the sufficient supply to penumbra area and, finally, inhibit neuronal death in the brain after stroke.

**MATERIALS AND METHODS**

The materials used in the experiment were rHu Erythropoietin alfa (PT Daewoong Infion), normal saline, distilled water, buffered-formalin 10%, hematoxylin-eosin (Sigma Aldrich), xylazine, midazolam, and VEGF antibody (Thermofisher).

**Animals**

Male 8-12 week-old rats (Rattus norvegicus), weighing 140-240 g were used. The rats were acclimated for 1-2 weeks in a group of 3 individuals per polypropylene cage. All animals were housed on a 12 h light/dark cycle at a temperature of 22-24°C and humidity of 40-50%. They were fed on commercial pellets (pellets 594, Indonesia) and tap water ad libitum. The number of animals used was 30. Animal care and experimentation were conducted in animal laboratory of Universitas Airlangga, Surabaya, Indonesia.

**Animal study design**

To examine whether treatment with EPO promote functional recovery, as inducer angiogenesis, rHUEPO (epoetin a, 3,000 IU/ 0.3 ml; PT. Daewoong Infion, Pasuruan, Indonesia) was intravenously administered in a dose of 1,000 IU (n=6); 5,000 IU (n=6), and 10,000 IU (n=6), daily for 7 days starting at 24 hours after rUCCAO. Doses of rHuEPO were selected based on previous studies (Wang et al 2004). Ischemic rats (n=6) treated with the same volume were used as a control group. All rats were euthanized 14 days after stroke. Three rats in each group were used to examine the effect of rHuEPO on brain levels of VEGF and large of infarct area.

**Induction of ischemia**

Transient right unilateral common carotid artery occlusion (rUCCAO) is the method for inducing stroke. Rats were anaesthetized with combination of ketamin (80 mg) and Xylazine (10 mg) intramuscularly. After the animals were deeply anaesthetized, they were kept in supine position under an operating lamp. A midline neck incision was done between manubrium and the
Behavioral assessment

The behaviors of the rats with transient rUCCAO surgery were examined before rUCCAO induction and on days 1, 3, and 7 after rUCCAO. In forelimb use asymmetry test (FUAT), the percentage of rat limb exploration in cylindrical tube showed a significant increase on the 7th day (p<0.05, Fig.1).

Histological assessment

In this study, the histologic appearance of brain tissue showed the number of normal and damaged body cells of the neurons in the thalamus area. Stroke group experienced the highest number of cell damage compared to other groups. The group with rHuEPO therapy and the group with rHuEPO 10000 IU experienced the least amount of damage (Fig. 2).

Immunohistochemistry

In this study, the immunohistochemistry appearance of brain tissue shows the VEGF expression in the thalamus area (Figs. 3 and 4).

DISCUSSION

Our data indicated that treatment with rHuEPO 24 hours after stroke for 7 days significantly improved motor function and reduced the number of damaged body cell
and induced angiogenesis via regulation of VEGF in ischemic stroke. Treatment with rHuEPO for 7 days significantly improved motor function.

Fig. 1  Effect of rHuEPO on the motor function of rats represented by the percentage of FUAT value. Measurements were performed on the sham group, stroke model, and stroke model with rHuEPO doses of 1000 IU, 5000 IU and 10,000 IU from day 0 to day 7. Significant differences were seen on day 7 in sham group vs stroke model (p = 0.0139), stroke model vs rHuEPO of 1,000 IU (p = 0.0121), stroke model vs rHuEPO of 5,000 IU (p = 0.0005) and stroke model vs rHuEPO of 10,000 IU (p = 0.0121). * p <0.05 vs stroke model.

Fig. 2. Hematoxylin eosin staining of brain samples 14 days after transient rUCCAO 90 min. A) Brain sections from sham (B) Stroke Model (C) Stroke Model + rHuEPO 1,000 IU (D Stroke Model + rHuEPO 5,000 IU and (E) Stroke Model + rHuEPO 10,000 IU. Infarct lesions were showed in thalamus area. Sections were examined at bregma -2.00 mm.

Thalamus is known to regulate the process of motion. The ventrolateral, ventroanterior and ventrointermedial parts of thalamus are responsible in coordination and initiation of movement. EPO treatment provides neuroprotection when initiated soon after injury, with beneficial effects largely attributed to decrease in neuronal apoptosis (Siren et al 2001). Hypoxia induces cells to respond through multiple gene products, such as EPO and VEGF, that will improve oxygen delivery to the tissues. The induction of EPO and EPOR by hypoxia suggests that EPO administration has a therapeutic potential role for tissue damage from ischemia or hypoxia in the central nervous system (Ribatti et al 2003). EPO has been shown to improve sensorimotor and cognitive deficits in rats after both CCI and cryogenic lesion injuries (Hellwell et al 2013), so it reduces cell death in the thalamus area and improves motor function in stroke.
Fig. 3. Immunohistochemistry with VEGF antibody. A) Brain sections from sham (B) Stroke Model (C) Stroke Model + rHuEPO 1,000 IU (D Stroke Model + rHuEPO 5,000 IU and (E) Stroke Model + rHuEPO 10,000 IU. VEGF expression was showed in thalamus area. Sections were examined at bregma -2.00 mm. 400x magnification was used.

Fig. 4. VEGF expressions were examined in the sham group, stroke model, and stroke model group with rHuEPO of 1,000 IU; 5,000 IU and 10,000 IU. Tukey's post-hoc test showed significant differences in the sham vs stroke model (p = 0.0135), sham vs rHuEPO 5000 IU (p=0.0007), (p=0.0191). *p<0.05 vs sham.

Immunohistochemistry results showed that rHuEPO with doses of 5,000 IU and 10,000 IU significantly increased VEGF expression. It is reported that EPO promotes angiogenesis by EPO binding to its receptor (EPOR), thus phosphorylates and activates Janus tyrosine kinase 2 (JAK2). This leads to engaging secondary signaling molecules, such as signal transducer and activator of transcription 5 (STAT5), followed by the activation of Ras mitogen activated protein kinase (MAPK), ERK-1/2, and PI3K/Akt. Moreover, EPO induced the upregulation of the anti-apoptotic protein BCL-XL (Rabie & Marti 2008). The PI3K/Akt and ERK1/2 signaling pathways mediates VEGF secretion after the binding of exogenous EPO with EPOR. VEGF secreted by neural progenitor cells along with VEGFR2 in cerebral endothelial cells promotes angiogenesis.
EPO induces angiogenesis through increasing VEGF expression (Wang et al 2004).

CONCLUSION

rHuEPO may restore motoric function and prevent brain neuronal death by inducing angiogenesis through the increase in the expression of VEGF.

ACKNOWLEDGMENT

This work was supported by research grants “Hibah Riset Tahun 2017” from the Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.

REFERENCES